Gilead Sciences (GILD 1.37%) and cancer drugmaker Forty Seven (FTSV) have reportedly agreed to an all-cash buyout worth $4.9 billion. Last week, Gilead was rumored to be in buyout or licensing talks with Forty Seven, with discussions centering around the biotech's novel monoclonal antibody, magrolimab, which blocks the CD47 "don't eat me" cell signaling pathway. Forty Seven's stock is up by 61.9% in premarket trading in response to this buyout news.
Gilead's shareholders also seem pleased with the deal. The biotech's stock is up by 1.3% on the heels of this major pipeline addition in oncology, despite the market's dour mood in general over the novel coronavirus outbreak. Fellow CD47 drugmaker Trillium Therapeutics (TRIL) is also on the move in the wake of this rather rich tender offer. Specifically, Trillium's stock jumped by as much as 65% in premarket trading Monday morning. Since hitting that premarket high, the biotech's shares have cooled off a bit, but they are still up by a healthy 44.7% as of 8:15 a.m EST.
This is a fantastic deal for Gilead in a multitude of ways. In a nutshell, the blue-chip biotech is gaining a well-differentiated, high-value oncology asset with magrolimab. Magrolimab has the potential to rack up numerous lucrative indications in both the solid and liquid tumor settings in the years ahead. We're talking several billion in peak annual sales if this drug lives up to the hype.
What about Trillium Therapeutics? Trillium Therapeutics stock is on fire this morning because of the perceived valuation gap between it and rival Forty Seven. Prior to this deal becoming public knowledge, Forty Seven's market cap was roughly 10 times that of Trillium Therapeutics. In short, investors appear to be speculating that Trillium Therapeutics will be the next CD47 drugmaker to fetch an offer, partly because of its far cheaper valuation.
Even after forking over close to $5 billion for Forty Seven, Gilead still has tons of cash left over to pursue other value-creating transactions this year. The next transaction, in fact, is likely to be a tuck-in acquisition that will have an immediate impact on the biotech's top line. In brief, Gilead could seriously use another near-term growth driver. This pipeline-oriented Forty Seven acquisition doesn't change that fact.
As far as Trillium's near-term prospects are concerned, it's probably a bad idea to chase this sympathy play today. Trillium's intriguing anti-cancer pipeline may attract a suitor at some point down the line, but it's highly unlikely that another deal in the exact same therapeutic area will occur anytime soon. That's just the nature of the mergers and acquisitions scene in biopharma.